<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347503</url>
  </required_header>
  <id_info>
    <org_study_id>B2601</org_study_id>
    <nct_id>NCT00347503</nct_id>
  </id_info>
  <brief_title>Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients</brief_title>
  <official_title>Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <brief_summary>
    <textblock>
      Evaluation of the aqueous concentrations of 2 topical NSAIDS as well as the PGE2 inhibition
      in human patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <condition>Cataract</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketorolac 0.4%, bromfenac 0.09%</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male/Female 21 years of age of older.

          -  Patient understands and is willing to sign the written informed consent form

          -  Likely to complete the entire course of the study.

          -  Patient is scheduled to undergo cataract surgery

          -  Female patients of childbearing potential must have had a regular menstrual cycle
             prior to study entry (a female is considered of childbearing potential unless she is
             postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal
             ligation).

          -  Patient is willing and able to administer eye drops and record the times the drops
             were instilled

        Exclusion Criteria:

          -  Patient has been using a topical NSAID within 1 week of study entry

          -  Patient has a known sensitivity to any of the ingredients in the study medications

          -  Patient has sight in only one eye

          -  Patient has a history of previous intraocular surgery

          -  Patientâ€™s doctor has determined they have a condition (i.e., UNCONTROLLED systemic
             disease) or are in a situation that may put them at significant risk, confound the
             study results or may interfere significantly with their participation in the study

          -  Female patients who are pregnant, nursing an infant or planning a pregnancy

          -  Patients who are currently involved in another investigational study or have
             participated in one within the 30 days prior to entering this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Bucci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Vision Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucci Laser Vision</name>
      <address>
        <city>Wilkes Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>July 12, 2007</last_update_submitted>
  <last_update_submitted_qc>July 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

